ABATEMENT OF POTENT P2Y12 ANTAGONIST-BASED DUAL ANTIPLATELET THERAPY AFTER CORONARY INTERVENTION: A NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Abatement of potent P2Y12 antagonist-based dual antiplatelet therapy after coronary intervention: A network meta-analysis of randomized controlled trials

IntroductionDual antiplatelet therapy (DAPT) including prasugrel or ticagrelor is NEEDLES AND SYRINGES recommended in patients with acute coronary syndromes (ACS) treated with coronary intervention (PCI).Acknowledging the importance of bleeding, multiple trials tested abatement schemes including uniform or guided de-escalation from the potent P2Y12

read more


Treating hepatitis C virus in children: time for a new paradigm

Hepatitis C virus infection is a leading cause of liver-related morbidity and mortality.In the paediatric population, HCV infection is underdiagnosed and undertreated Distribution Block in the absence of robust screening policies worldwide, and a lack of tolerable, effective treatment.The recent advances in HCV drug development allow for optimism,

read more